Atlas Trials

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Clinical trial NCT03393845 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03393845
Sponsor
Nancy Chan, MD
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2018-01-29
Primary completion
2023-08-04
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.